Ora announced that David P. Bingaman, DVM, PhD, D. ACVO has joined the company in a newly created role of Chief Development Officer (CDO).
Dr. Bingaman will oversee clinical and nonclinical activities that directly impact Ora’s customers around the world. Ora’s clinical research spans all ophthalmic indications, where global teams focused on each subspecialty bring unparalleled operational insights and execution to the company’s customers. Ora’s concept-to-clinic services comprise ophthalmology-dedicated CMC and regulatory teams, as well as preclinical experts with deep translational science experience.
“For 45 years, innovators of ophthalmic products have relied upon Ora’s experienced people and our disciplined approach to innovating research methods and operational excellence,” President, Chairman, and CEO Stuart B. Abelson said in a company news release. “Dr. Bingaman’s background and leadership characteristics will ensure that Ora continues to consistently deliver outstanding development programs amidst increasing global demand for our knowledge, services, and technologies.”
“Ora’s breadth of knowledge and innovative spark are remarkable,” said Dr. Bingaman. “Their collaborative approach and can-do attitude make a transformational difference to client projects. I am honored to work with this incredibly accomplished team to continue to scale Ora’s great work for customers, partners, and patients around the world.”
Dr. Bingaman is a board-certified Veterinary Ophthalmologist with a PhD in Ocular Angiogenesis and deep roots in translational science. He also holds multiple patents and has authored numerous book chapters and peer-reviewed publications.
Throughout his career, Dr. Bingaman has established programs to study vision diseases with unmet medical needs, led clinical and nonclinical ophthalmic development strategies for early- and late-phase programs, and served as a collaborative, humble thought leader in the global ophthalmic space.
Before joining Ora, Dr. Bingaman served in large, public entities and small, privately held biotechnology companies. Prior employers include Alcon Laboratories, Alcon/Novartis, PanOptica, and, most recently, Oculis, where he held the role of Vice President and Head of Global Clinical Development.